Group One Trading’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.3K | Sell |
7,872
-5,350
| -40% | -$11.3K | ﹤0.01% | 6072 |
|
|
2026
Q1 | $28.7K | Buy |
+13,222
| New | +$32.8K | ﹤0.01% | 5703 |
|
|
2025
Q1 | – | Sell |
-656
| Closed | -$1.57K | – | 8199 |
|
|
2024
Q4 | $1.23K | Buy |
+656
| New | +$928 | ﹤0.01% | 6852 |
|
|
2022
Q2 | – | Sell |
-32,646
| Closed | -$38.2K | – | 8353 |
|
|
2022
Q1 | $35K | Sell |
32,646
-597,900
| -95% | -$548K | ﹤0.01% | 6375 |
|
|
2021
Q4 | $524K | Buy |
630,546
+407,993
| +183% | +$427K | ﹤0.01% | 4083 |
|
|
2021
Q3 | $296K | Buy |
222,553
+43,465
| +24% | +$66.1K | ﹤0.01% | 4763 |
|
|
2021
Q2 | $342K | Buy |
+179,088
| New | +$616K | ﹤0.01% | 4643 |
|
|
2021
Q1 | – | Sell |
-50,280
| Closed | -$234K | – | 7924 |
|
|
2020
Q4 | $183K | Buy |
+50,280
| New | +$180K | ﹤0.01% | 4117 |
|
|
2020
Q2 | – | Sell |
-5,969
| Closed | -$20.4K | – | 6089 |
|
|
2020
Q1 | $14K | Buy |
5,969
+700
| +13% | +$2.31K | ﹤0.01% | 4424 |
|
|
2019
Q4 | $17K | Sell |
5,269
-17,511
| -77% | -$43.1K | ﹤0.01% | 4420 |
|
|
2019
Q3 | $47K | Buy |
22,780
+491
| +2% | +$1.47K | ﹤0.01% | 3998 |
|
|
2019
Q2 | $105K | Buy |
22,289
+18,118
| +434% | +$76.5K | ﹤0.01% | 3312 |
|
|
2019
Q1 | $18K | Buy |
4,171
+1,810
| +77% | +$8.16K | ﹤0.01% | 4069 |
|
|
2018
Q4 | $7K | Sell |
2,361
-1,475
| -38% | -$7.01K | ﹤0.01% | 4391 |
|
|
2018
Q3 | $28K | Buy |
+3,836
| New | +$19.3K | ﹤0.01% | 4270 |
|
|
2016
Q4 | – | Sell |
-37
| Closed | – | – | 4743 |
|
|
2016
Q3 | $0 | Hold |
37
| – | – | ﹤0.01% | 4818 |
|
|
2016
Q2 | $0 | Hold |
37
| – | – | ﹤0.01% | 4874 |
|
|
2016
Q1 | $0 | Buy |
+37
| New | +$317 | ﹤0.01% | 4853 |
|
|
2015
Q3 | – | Sell |
-1,272
| Closed | -$20.2K | – | 5113 |
|
|
2015
Q2 | $25K | Sell |
1,272
-1,181
| -48% | -$24.5K | ﹤0.01% | 3930 |
|
|
2015
Q1 | $44K | Buy |
2,453
+568
| +30% | +$11.1K | ﹤0.01% | 3434 |
|
|
2014
Q4 | $35K | Sell |
1,885
-8,907
| -83% | -$191K | ﹤0.01% | 3616 |
|
|
2014
Q3 | $261K | Sell |
10,792
-4,313
| -29% | -$124K | ﹤0.01% | 2173 |
|
|
2014
Q2 | $551K | Buy |
15,105
+7,624
| +102% | +$308K | 0.01% | 1564 |
|
|
2014
Q1 | $343K | Buy |
7,481
+2,949
| +65% | +$138K | 0.01% | 1967 |
|
|
2013
Q4 | $176K | Sell |
4,532
-1,804
| -28% | -$76K | ﹤0.01% | 2548 |
|
|
2013
Q3 | $287K | Buy |
6,336
+4,048
| +177% | +$208K | 0.01% | 2070 |
|
|
2013
Q2 | $112K | Buy |
+2,288
| New | +$121K | ﹤0.01% | 2712 |
|
Other funds holding PLX
SWP
Group One Trading's PLX Position: Q2 2026 in Review
Group One Trading reduced its Protalix BioTherapeutics (PLX) stake by 40% in Q2 2026, selling an estimated $11.3K and leaving 7,872 shares worth $18.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6072.
Group One Trading first reported a position in PLX in Q2 2013 and has held it in 27 quarters since. The position peaked at $551K in Q2 2014. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.
- Group One Trading held 7,872 shares of Protalix BioTherapeutics worth $18.3K as of Q2 2026.
- Group One Trading sold 5,350 Protalix BioTherapeutics shares in Q2 2026, an estimated $11.3K.
- Protalix BioTherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6072 holding.
- Group One Trading first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 27 quarters since.
- Group One Trading's Protalix BioTherapeutics position peaked at $551K in Q2 2014.
- 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.